Penn’s Innovation in Process Science combines with CBM manufacturing capability to develop large-scale gene therapy manufacturing capacity, testing, and analytics
Drs. Katalin Kariko and Drew Weissman, inventors of the foundational RNA research that led to the COVID-19 vaccines, are two of researchers named by Time Magazine as their Heroes of the Year 2021.
Passage Bio has exercised two additional options for potential new drug candidates under its research collaboration with Penn's gene therapy program.
The event honors the patent recipients from the previous fiscal year, as well as, those partners, inventors, and startups that made exceptional achievements.
She will serve as a member of REGENXBIO's Nominating and Corporate Governance Committee.
The biotech will use the funds for a slate of gene insertion programs for liver disorders out of the lab of gene therapy pioneer Jim Wilson, M.D., Ph.D. at Penn.
One of Tachi’s newly born legacy biotechs raises $135M and enlists an A-list board to advance late-stage vaccine
Tachi Yamada's biotechs are continuing to make news.
The U.S. FDA has given the first full approval to a COVID-19 mRNA vaccine, which uses modified mRNA technology invented and developed by scientists at Penn.
The Daily podcast by the New York Times interviewed Dr. Katalin Kariko about the long road to getting mRNA into the vaccines that are winning the war against COVID.
PCI’s Managing Director leads panel discussion on Cellicon Valley with Penn Medicine faculty luminaries
On May 6th, as part of the Cellicon Valley '21 two-day event, John Swartley, Managing Director of PCI, joined Penn Medicine faculty to discuss the commercialization of CAR-T technology